US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count
Executive Summary
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
You may also be interested in...
As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran
Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.
Roxadustat Stacks Up To Darbepoietin In Non-Dialysis Anemia
Astellas’s oral HIF-PH inhibitor shows non-inferiority to one established ESA in head-to-head trial and while there were cardiovascular benefits, the picture is complex.
US FDA’s Median Review Time For Novel Drugs Held Steady In 2020
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: